High level amplification of N-MYC is not associated with adverse histology or outcome in primary retinoblastoma tumours

British Journal of Cancer

Volumn 87, Issue 7, 2002, Pages 779-782

  Lillington, D M ^a   Goff, L K ^a   Kingston, J E ^b   Onadim, Z ^b   Price, E ^b   Domizio, P ^b   Young, B D ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

N MYC; Outcome; Real time quantitative polymerase chain reaction (RQ PCR); Retinoblastoma

Indexed keywords

PROTEIN C MYB;

ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME MAP; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ONCOGENE C MYB; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RETINOBLASTOMA;

DNA, NEOPLASM; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETINOBLASTOMA; SURVIVAL ANALYSIS;

EID: 0037163737     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600532     Document Type: Article

References (26)

1. Benedict WF, Banerjee A, Mark C, Murphree AL (1983) Nonrandom chromosomal changes in untreated retinoblastomas. Cancer Genet Cytogenet 10: 311-333
2. Bieche I, Olivi M, Champeme M-H, Vidaud D, Lidereau R, Vidaud M (1998) Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer 78: 661-666
3. Chen D, Gallie BL, Squire JA (2001) Minimal regions of chromosomal imbalance in retinoblastoma detected by comparative genomic hybridization. Cancer Genet Cytogenet 129: 57-63
4. Draper GJ, Sanders BM, Kingston JE (1986) Second primary neoplasms in patients with retinoblastoma. Br J Cancer 53: 661-671
5. Ferrando AA, Look AT (2000) Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. Semin Hematol 37: 381-395
6. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323: 643-646
7. George RK, Variend S, Cullinane C, Cotterill SJ, McGuckin AG, Ellershaw C, Lunec J, Pearson AD (2001) Relationship between histopathological features, MYCN amplification and prognosis: a UKCCSG study. United Kingdom Cancer Study Group. Med Pediatr Oncol 36: 169-176
8. Goff LK, Neat MJ, Crawley CR, Jones L, Jones E, Lister TA, Gupta RK (2000) The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma. Br J Haematol 111: 618-625
9. Herzog S, Lohmann DR, Buiting K, Schuler A, Horsthemke B, Rehder H, Rieder H (2001) Marked differences in unilateral retinoblastomas from young and older children studied by comparative genomic hybridization. Hum Genet 108: 98-104
10. Khelfaoui F, Validire P, Auperin A, Quintana E, Michon J, Pacquement H, Desjardins L, Asselain B, Schlienger P, Viehl P, Dufier J-L, Zucker J-M, Doz F (1996) Histopathologic risk factors in retinoblastoma. Cancer 77: 1206-1213
11. Kim CJ, Chi JG, Choi HS, Shin HY, Ahn HS, Yoo YS, Chang KY (1999) Proliferation not apoptosis as a prognostic indicator in retinoblastoma. Virchows Archive 434: 301-305
12. Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-823
13. Knudson AG (1976) Genetics and the aetiology of childhood cancer. Pediat Res 10: 513-517
14. Lasorella A, Boldrini R, Dominici C, Donfrancesco A, Yokota Y, Inserra A, Iavarone A (2002) Id2 is critical for cellular proliferation and is the oncogenic effector of N-Myc in human neuroblastoma. Cancer Res 62: 301-306
15. Lastowska M, Cullinane C, Variend S, Cotterill S, Bown N, O'Neill S, Mazzocco K, Roberts P, Nicholson J, Ellershaw C, Pearson AD, Jackson MS (2001) Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 19: 3080-3090
16. Mairal A, Pinglier E, Gilbert E, Peter M, Validire M, Desjardins L, Doz F, Aurias A, Couturier J (2000) Detection of chromosome imbalances in retinoblastoma by parallel karyotype and CGH analyses. Genes, Chromosomes Cancer 28: 370-379
17. Misra RR, Pinsky PF, Srivastava S (2000) Prognostic factors for hematologic cancers. Hematol Oncol Clin North Am 14: 907-924
18. Mitelman F (2001) Mitelman database of chromosome --------1aberrations in cancer, National Cancer Institute (http://cgap.nci.nih.gov/chromosomes/Mitelman).
19. Mrozek K, Heinonen K, Bloomfield CD (2000) Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. Int J Hematol 72: 261-271
20. Mrozek K, Heinonen K, Bloomfield CD (2001) Clinical importance of cytogenetics in acute myeloid leukaemia. Baillieres Best Pract Res Clin Haematol 14: 19-47
21. Oliveros O, Yunis E (1995) Chromosome evolution in retinoblastoma. Cancer Genet Cytogenet 82: 155-160
22. Orjuela M, Castaneda VP, Ridaura C, Lecona E, Leal C, Abramson DH, Orlow I, Gerald W, Cordon-Cardo C (2000) Presence of human papilloma virus in tumor tissue from children with retinoblastoma: an alternative mechanism for tumor development. Clin Cancer Research 6: 4010-4016
23. Roarty JD, McLean IW, Zimmerman LE (1988) Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology 95: 1583-1587
24. Squire j, Gallie BL, Phillips RA (1985) A detailed analysis of chromosomal changes in heritable and non-heritable retinoblastoma. Hum Genet 70: 291-301
25. Tajiri T, Tanaka S, Shono K, Kinoshita Y, Fujii Y, Suita S, Ihara K, Hara T (2001) Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma. Cancer Lett 166: 89-94
26. Taylor CP, Bown NP, McGuckin AG, Lunec J, Malcolm AJ, Pearson AD, Sheer D (2000) Fluorescence in situ hybridization techniques for the rapid detection of genetic prognostic factors in neuroblastoma. United Kingdom Children's Cancer Study Group. Br j Cancer 83: 40-49